Skip to main content

Advertisement

Table 1 Clinical and biological characteristics of the study population

From: RNY-derived small RNAs as a signature of coronary artery disease

  Cases (n = 263) Controls (n = 514) P value
Age (years) 60.3 (8.0) 59.0 (8.3) 0.04
Education (years of schooling) 9.6 (3.0) 13.1 (4.3) 0.001 a
Alcohol (g/day) 28.8 (28.5) 23.8 (24.1) 0.09 a
Tobacco consumption number (pack/year) 41.5 (37.9) 17.2 (21.3) 0.001 a
Physical activity (%)    0.001
 No 27.4 18.5  
 Medium 61.6 45.9  
 High 11.0 35.6  
Waist (cm) 99.3 (10.7) 95.3 (9.9) 0.001
Body mass index (kg/m2) 27.5 (4.0) 26.9 (3.6) 0.04
Total cholesterol (g/L) 2.02 (0.38) 2.24 (0.38) 0.001
HDL-cholesterol (g/L) 0.43 (0.12) 0.55 (0.13) 0.001
LDL-cholesterol (g/L) 1.25 (0.34) 1.45 (0.32) 0.001
Triglyceride (g/L) 1.68 (0.89) 1.21 (0.77) 0.001 b
ApoA-I (g/L) 1.23 (0.22) 1.50 (0.24) 0.001
ApoB (g/L) 1.04 (0.22) 1.08 (0.22) 0.03
Lipoprotein (a) (g/L) 0.47 (0.44) 0.30 (0.37) 0.001 b
hs-CRP (mg/L) 17.2 (29.7) 3.1 (5.1) 0.001 a
Gamma glutamyl transferase (IU/L) 62.8 (68.6) 45.2 (56.8) 0.001 a
Fasting glucose (mmol/L) 5.93 (2.01) 5.43 (1.06) 0.19 a
Serum insulin (UI/L) 15.9 (19.5) 10.0 (8.1) 0.001 a
HOMA-IR 4.2 (4.8) 2.6 (2.8) 0.001 a
Metabolic syndrome (NCEP ATP-III %) 48.5 17.7 0.001
Systolic blood pressure (mmHg) 137.0 (20.2) 137.4 (16.5) 0.82 a
Resting heart rate (beat/mn) 63.7 (11.5) 62.8 (9.2) 0.79 a
Ankle-arm index ≤0.9 (%) 33.6 1.6 0.001
Treatment for hypertension (%) 44.1 19.6 0.001
Treatment for diabetes (%) 23.2 5.2 0.001
Treatment for dyslipidemia (%) 63.5 23.3 0.001
s-RNY1-5p 10.42 (12.33) 1.32 (1.67) 0.001 a
(RNY1-5p)1/7 1.33 (0.18) 0.95 (0.19) 0.001
Quartiles RNY1-5p (%)    0.001
 Q1 : <0.47 0.4 37.9  
 Q2 : 0.47–1.62 5.3 34.6  
 Q3 : 1.61–4.70 28.5 23.4  
 Q4 : >4.70 65.8 4.1  
  1. Data are expressed as mean (±SD) or percentage (%)
  2. a Wilcoxon–Mann–Whitney test
  3. b Analyses performed on log transformed data
  4. ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; hs-CRP, High sensitive C-reactive protein; HOMA-IR, Homeostatic model assessment-insulin resistance; NCEP ATP-III, National Cholesterol Education Program’s Adult Treatment Panel III report